Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1986 Apr;77(4):1057–1062. doi: 10.1172/JCI112404

Defective postbinding lysis underlies the impaired natural killer activity in factor VIII-treated, human T lymphotropic virus type III seropositive hemophiliacs.

M Katzman, M M Lederman
PMCID: PMC424439  PMID: 3007575

Abstract

We investigated the diminished natural killer (NK) activity in human T lymphotropic virus type III (HTLV-III) seropositive hemophiliacs. Despite normal percentages of NK cells, lymphocytes from five hemophiliacs showed impaired NK activity against K-562 tumor cells in 4-h chromium release microcytotoxicity assays. For example, at an effector-to-target cell ratio of 10:1, cells from patients caused 21.7 +/- 2.5% lysis of tumor targets compared with 47.9 +/- 5.1% lysis by cells from controls (mean +/- SEM, P less than 0.005). Cells from patients were as cytotoxic in 18 h as were cells from controls in 4 h. Binding to tumor targets was not impaired since 11.0 +/- 1.5% of cells from patients and 11.1 +/- 1.3% of cells from controls bound to K-562 cells. Patients' binding cells, however, showed defective killing of attached tumor cells at all time points tested from 0 to 18 h. At 4 h, for example, patients' cells had lysed 10.9 +/- 2.1% of attached tumor cells compared with 26.3 +/- 3.3% lysis by controls' cells (P less than 0.005). The percentage of lymphocytes which were active NK cells (i.e., cells that bound and lysed a tumor cell) was always lower for patients than for controls (1.17 +/- 0.25% vs. 2.82 +/- 0.33%, P less than 0.005). Two methods for estimating recycling of effector cells against multiple target cells demonstrated that active NK cells from patients could recycle as well as those from controls (approximately 3-4 times in 4 h). Mixing experiments showed no evidence for cellular suppression of NK activity. The lytic function of NK cells from HTLV-III seropositive hemophiliacs is thus heterogeneous. This is characterized by a defect in post-binding lysis, with relative sparing of binding capability and recycling capacity.

Full text

PDF
1057

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Gascón P., Zoumbos N. C., Young N. S. Immunologic abnormalities in patients receiving multiple blood transfusions. Ann Intern Med. 1984 Feb;100(2):173–177. doi: 10.7326/0003-4819-100-2-173. [DOI] [PubMed] [Google Scholar]
  2. Gjerset G. F., Martin P. J., Counts R. B., Fast L. D., Hansen J. A. Immunologic status of hemophilia patients treated with cryoprecipitate or lyophilized concentrate. Blood. 1984 Sep;64(3):715–720. [PubMed] [Google Scholar]
  3. Grimm E., Bonavida B. Mechanism of cell-mediated cytotoxicity at the single cell level. I. Estimation of cytotoxic T lymphocyte frequency and relative lytic efficiency. J Immunol. 1979 Dec;123(6):2861–2869. [PubMed] [Google Scholar]
  4. Kaplan J., Sarnaik S., Gitlin J., Lusher J. Diminished helper/suppressor lymphocyte ratios and natural killer activity in recipients of repeated blood transfusions. Blood. 1984 Jul;64(1):308–310. [PubMed] [Google Scholar]
  5. Kaplan J., Sarnaik S., Levy J. Transfusion-induced immunologic abnormalities not related to AIDS virus. N Engl J Med. 1985 Nov 7;313(19):1227–1227. doi: 10.1056/NEJM198511073131912. [DOI] [PubMed] [Google Scholar]
  6. Katz P., Zaytoun A. M., Fauci A. S. Deficiency of active natural killer cells in the Chediak-Higashi syndrome. Localization of the defect using a single cell cytotoxicity assay. J Clin Invest. 1982 Jun;69(6):1231–1238. doi: 10.1172/JCI110562. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Landay A., Poon M. C., Abo T., Stagno S., Lurie A., Cooper M. D. Immunologic studies in asymptomatic hemophilia patients. Relationship to acquired immune deficiency syndrome (AIDS). J Clin Invest. 1983 May;71(5):1500–1504. doi: 10.1172/JCI110904. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lane H. C., Fauci A. S. Immunologic abnormalities in the acquired immunodeficiency syndrome. Annu Rev Immunol. 1985;3:477–500. doi: 10.1146/annurev.iy.03.040185.002401. [DOI] [PubMed] [Google Scholar]
  9. Lanier L. L., Le A. M., Phillips J. H., Warner N. L., Babcock G. F. Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. J Immunol. 1983 Oct;131(4):1789–1796. [PubMed] [Google Scholar]
  10. Lederman M. M., Ratnoff O. D., Evatt B. L., McDougal J. S. Acquisition of antibody to lymphadenopathy-associated virus in patients with classic hemophilia (factor VIII deficiency). Ann Intern Med. 1985 Jun;102(6):753–757. doi: 10.7326/0003-4819-102-6-753. [DOI] [PubMed] [Google Scholar]
  11. Lederman M. M., Ratnoff O. D., Schacter B., Shoger T. Impaired cell-mediated immunity in hemophilia. II. Persistence of subclinical immunodeficiency and enhancement of natural killer activity by lymphokines. J Lab Clin Med. 1985 Aug;106(2):197–204. [PubMed] [Google Scholar]
  12. Lederman M. M., Ratnoff O. D., Scillian J. J., Jones P. K., Schacter B. Impaired cell-mediated immunity in patients with classic hemophilia. N Engl J Med. 1983 Jan 13;308(2):79–83. doi: 10.1056/NEJM198301133080205. [DOI] [PubMed] [Google Scholar]
  13. Lifson J. D., Benike C. J., Mark D. F., Koths K., Engleman E. G. Human recombinant interleukin-2 partly reconstitutes deficient in-vitro immune responses of lymphocytes from patients with AIDS. Lancet. 1984 Mar 31;1(8379):698–702. doi: 10.1016/s0140-6736(84)92220-7. [DOI] [PubMed] [Google Scholar]
  14. Montagnier L., Gruest J., Chamaret S., Dauguet C., Axler C., Guétard D., Nugeyre M. T., Barré-Sinoussi F., Chermann J. C., Brunet J. B. Adaptation of lymphadenopathy associated virus (LAV) to replication in EBV-transformed B lymphoblastoid cell lines. Science. 1984 Jul 6;225(4657):63–66. doi: 10.1126/science.6328661. [DOI] [PubMed] [Google Scholar]
  15. Porzsolt F., Hauser M., Piper C., Scholz S., Stötter H., Pindur G., Seifried E., Rasche H. Impaired natural killer cell function in hemophiliacs with or without continuous substitution. Blut. 1984 Jul;49(1):61–65. doi: 10.1007/BF00320385. [DOI] [PubMed] [Google Scholar]
  16. Pross H. F., Baines M. G., Rubin P., Shragge P., Patterson M. S. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol. 1981 Jan;1(1):51–63. doi: 10.1007/BF00915477. [DOI] [PubMed] [Google Scholar]
  17. Ratnoff O. D., Menitove J. E., Aster R. H., Lederman M. M. Coincident classic hemophilia and "idiopathic" thrombocytopenic purpura in patients under treatment with concentrates of antihemophilic factor (factor VIII). N Engl J Med. 1983 Feb 24;308(8):439–442. doi: 10.1056/NEJM198302243080808. [DOI] [PubMed] [Google Scholar]
  18. Reddy M. M., Pinyavat N., Grieco M. H. Interleukin 2 augmentation of natural killer cell activity in homosexual men with acquired immune deficiency syndrome. Infect Immun. 1984 May;44(2):339–343. doi: 10.1128/iai.44.2.339-343.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Rook A. H., Masur H., Lane H. C., Frederick W., Kasahara T., Macher A. M., Djeu J. Y., Manischewitz J. F., Jackson L., Fauci A. S. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest. 1983 Jul;72(1):398–403. doi: 10.1172/JCI110981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Salahuddin S. Z., Groopman J. E., Markham P. D., Sarngadharan M. G., Redfield R. R., McLane M. F., Essex M., Sliski A., Gallo R. C. HTLV-III in symptom-free seronegative persons. Lancet. 1984 Dec 22;2(8417-8418):1418–1420. doi: 10.1016/s0140-6736(84)91619-2. [DOI] [PubMed] [Google Scholar]
  21. Siegal F. P., Lopez C., Hammer G. S., Brown A. E., Kornfeld S. J., Gold J., Hassett J., Hirschman S. Z., Cunningham-Rundles C., Adelsberg B. R. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med. 1981 Dec 10;305(24):1439–1444. doi: 10.1056/NEJM198112103052403. [DOI] [PubMed] [Google Scholar]
  22. Steinhauer E. H., Doyle A. T., Reed J., Kadish A. S. Defective natural cytotoxicity in patients with cancer: normal number of effector cells but decreased recycling capacity in patients with advanced disease. J Immunol. 1982 Nov;129(5):2255–2259. [PubMed] [Google Scholar]
  23. Targan S. R., Oseas R. The "lazy" NK cells of Chediak-Higashi syndrome. J Immunol. 1983 Jun;130(6):2671–2674. [PubMed] [Google Scholar]
  24. Ullberg M., Jondal M. Recycling and target binding capacity of human natural killer cells. J Exp Med. 1981 Mar 1;153(3):615–628. doi: 10.1084/jem.153.3.615. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES